JPWO2021211885A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021211885A5 JPWO2021211885A5 JP2022562312A JP2022562312A JPWO2021211885A5 JP WO2021211885 A5 JPWO2021211885 A5 JP WO2021211885A5 JP 2022562312 A JP2022562312 A JP 2022562312A JP 2022562312 A JP2022562312 A JP 2022562312A JP WO2021211885 A5 JPWO2021211885 A5 JP WO2021211885A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- mbv
- hours
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 77
- 208000015181 infectious disease Diseases 0.000 claims description 20
- 210000004072 lung Anatomy 0.000 claims description 20
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 17
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 13
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 13
- 208000003322 Coinfection Diseases 0.000 claims description 12
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 10
- 210000000952 spleen Anatomy 0.000 claims description 10
- 108090000695 Cytokines Proteins 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 8
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 8
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 8
- 210000002744 extracellular matrix Anatomy 0.000 claims description 8
- 238000001990 intravenous administration Methods 0.000 claims description 8
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 8
- 150000003904 phospholipids Chemical class 0.000 claims description 8
- 102100034283 Annexin A5 Human genes 0.000 claims description 6
- 102100025222 CD63 antigen Human genes 0.000 claims description 6
- 102100027221 CD81 antigen Human genes 0.000 claims description 6
- 101000780122 Homo sapiens Annexin A5 Proteins 0.000 claims description 6
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 claims description 6
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 claims description 6
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims description 6
- 101000613251 Homo sapiens Tumor susceptibility gene 101 protein Proteins 0.000 claims description 6
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 6
- 102100040879 Tumor susceptibility gene 101 protein Human genes 0.000 claims description 6
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 6
- 230000000840 anti-viral effect Effects 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 230000037396 body weight Effects 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 239000011159 matrix material Substances 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 230000002685 pulmonary effect Effects 0.000 claims description 6
- 210000003932 urinary bladder Anatomy 0.000 claims description 6
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 4
- 206010050685 Cytokine storm Diseases 0.000 claims description 4
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims description 4
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 4
- 241000282414 Homo sapiens Species 0.000 claims description 4
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims description 4
- 102000015617 Janus Kinases Human genes 0.000 claims description 4
- 108010024121 Janus Kinases Proteins 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 4
- 206010052015 cytokine release syndrome Diseases 0.000 claims description 4
- 210000002216 heart Anatomy 0.000 claims description 4
- 238000010253 intravenous injection Methods 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 4
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 4
- 230000000770 proinflammatory effect Effects 0.000 claims description 4
- 238000005070 sampling Methods 0.000 claims description 4
- 230000009885 systemic effect Effects 0.000 claims description 4
- 210000004876 tela submucosa Anatomy 0.000 claims description 4
- 231100000167 toxic agent Toxicity 0.000 claims description 4
- 239000003440 toxic substance Substances 0.000 claims description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 claims description 2
- 101100165655 Arabidopsis thaliana BRO1 gene Proteins 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 241000283690 Bos taurus Species 0.000 claims description 2
- 102100032912 CD44 antigen Human genes 0.000 claims description 2
- 208000025721 COVID-19 Diseases 0.000 claims description 2
- 241001678559 COVID-19 virus Species 0.000 claims description 2
- 241000282693 Cercopithecidae Species 0.000 claims description 2
- 206010061386 Chest injury Diseases 0.000 claims description 2
- 241000701022 Cytomegalovirus Species 0.000 claims description 2
- 241001115402 Ebolavirus Species 0.000 claims description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 2
- 102100032564 Golgin subfamily A member 2 Human genes 0.000 claims description 2
- 108010074556 Golgin subfamily A member 2 Proteins 0.000 claims description 2
- 206010019196 Head injury Diseases 0.000 claims description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 2
- 101000847538 Homo sapiens Flotillin-1 Proteins 0.000 claims description 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims description 2
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims description 2
- 101100082597 Homo sapiens PDCD6IP gene Proteins 0.000 claims description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 2
- -1 IL-1β Proteins 0.000 claims description 2
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 2
- 102100037850 Interferon gamma Human genes 0.000 claims description 2
- 108010074328 Interferon-gamma Proteins 0.000 claims description 2
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims description 2
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 claims description 2
- 102000003814 Interleukin-10 Human genes 0.000 claims description 2
- 108090000174 Interleukin-10 Proteins 0.000 claims description 2
- 108090000978 Interleukin-4 Proteins 0.000 claims description 2
- 102000004388 Interleukin-4 Human genes 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 102000004889 Interleukin-6 Human genes 0.000 claims description 2
- 108090001007 Interleukin-8 Proteins 0.000 claims description 2
- 102000004890 Interleukin-8 Human genes 0.000 claims description 2
- 102100033467 L-selectin Human genes 0.000 claims description 2
- 208000025370 Middle East respiratory syndrome Diseases 0.000 claims description 2
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 241001494479 Pecora Species 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 102100033344 Programmed cell death 6-interacting protein Human genes 0.000 claims description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 2
- 102100029753 Reduced folate transporter Human genes 0.000 claims description 2
- 241000315672 SARS coronavirus Species 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 241000282898 Sus scrofa Species 0.000 claims description 2
- 208000029224 Thoracic injury Diseases 0.000 claims description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 210000000577 adipose tissue Anatomy 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 229960004238 anakinra Drugs 0.000 claims description 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 2
- 229960004099 azithromycin Drugs 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 210000004204 blood vessel Anatomy 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 210000004443 dendritic cell Anatomy 0.000 claims description 2
- 210000004207 dermis Anatomy 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims description 2
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 claims description 2
- 229950008454 favipiravir Drugs 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 239000003517 fume Substances 0.000 claims description 2
- 230000002538 fungal effect Effects 0.000 claims description 2
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960004171 hydroxychloroquine Drugs 0.000 claims description 2
- 230000004957 immunoregulator effect Effects 0.000 claims description 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
- 230000001861 immunosuppressant effect Effects 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 229940071648 metered dose inhaler Drugs 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 239000006199 nebulizer Substances 0.000 claims description 2
- 210000000440 neutrophil Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 210000002826 placenta Anatomy 0.000 claims description 2
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 claims description 2
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 claims description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 2
- 210000000813 small intestine Anatomy 0.000 claims description 2
- 239000000779 smoke Substances 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical group C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 2
- 230000000451 tissue damage Effects 0.000 claims description 2
- 231100000827 tissue damage Toxicity 0.000 claims description 2
- 229960003989 tocilizumab Drugs 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 210000004291 uterus Anatomy 0.000 claims description 2
- 210000003462 vein Anatomy 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 210000004916 vomit Anatomy 0.000 claims description 2
- 230000008673 vomiting Effects 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 210000000707 wrist Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 59
- 238000001802 infusion Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063011177P | 2020-04-16 | 2020-04-16 | |
| US63/011,177 | 2020-04-16 | ||
| PCT/US2021/027542 WO2021211885A1 (fr) | 2020-04-16 | 2021-04-15 | Vésicules liées à une matrice (mbv) pour le traitement du syndrome de détresse respiratoire aiguë |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023521831A JP2023521831A (ja) | 2023-05-25 |
| JPWO2021211885A5 true JPWO2021211885A5 (fr) | 2024-04-23 |
Family
ID=78084676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022562312A Pending JP2023521831A (ja) | 2020-04-16 | 2021-04-15 | 急性呼吸窮迫症候群の処置のためのマトリックス結合小胞（ｍｂｖ） |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230071393A1 (fr) |
| EP (1) | EP4135727A4 (fr) |
| JP (1) | JP2023521831A (fr) |
| KR (1) | KR20230007389A (fr) |
| CN (1) | CN115515607A (fr) |
| AU (1) | AU2021257444A1 (fr) |
| CA (1) | CA3180193A1 (fr) |
| WO (1) | WO2021211885A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3618841B1 (fr) | 2017-05-05 | 2023-03-22 | University of Pittsburgh - of The Commonwealth System of Higher Education | Applications oculaires de vésicules liées à une matrice (mbvs) |
| EP4210716A4 (fr) * | 2020-09-14 | 2024-09-04 | Univ California | Compositions et méthodes d'utilisation pour matrice extracellulaire infusible |
| WO2023250436A1 (fr) * | 2022-06-24 | 2023-12-28 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Utilisation de vésicules liées à une matrice (mbv) en tant qu'adjuvants de vaccin |
| CN117582444B (zh) * | 2023-10-12 | 2024-04-30 | 中国科学院微生物研究所 | Gs-9620在制备预防和/或治疗银屑病的药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009014633A1 (fr) * | 2007-07-20 | 2009-01-29 | Trustees Of The University Of Pennsylvania | Procédé de traitement du syndrome de détresse respiratoire aiguë |
| WO2016112271A1 (fr) * | 2015-01-08 | 2016-07-14 | The Johns Hopkins University | Compositions et procédés d'accélération de la résolution d'une inflammation pulmonaire aiguë |
| EP3618841B1 (fr) * | 2017-05-05 | 2023-03-22 | University of Pittsburgh - of The Commonwealth System of Higher Education | Applications oculaires de vésicules liées à une matrice (mbvs) |
| KR20210005942A (ko) * | 2018-05-03 | 2021-01-15 | 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | Il-33을 포함하는 매트릭스 결합 소포 (mbvs) 및 그 용도 |
-
2021
- 2021-04-15 US US17/904,287 patent/US20230071393A1/en active Pending
- 2021-04-15 KR KR1020227039963A patent/KR20230007389A/ko active Search and Examination
- 2021-04-15 JP JP2022562312A patent/JP2023521831A/ja active Pending
- 2021-04-15 WO PCT/US2021/027542 patent/WO2021211885A1/fr unknown
- 2021-04-15 CN CN202180029030.3A patent/CN115515607A/zh active Pending
- 2021-04-15 CA CA3180193A patent/CA3180193A1/fr active Pending
- 2021-04-15 EP EP21788702.5A patent/EP4135727A4/fr active Pending
- 2021-04-15 AU AU2021257444A patent/AU2021257444A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Montgomery et al. | Aerosolised pentamidine as sole therapy for Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome | |
| Ashbaugh et al. | Acute respiratory distress in adults | |
| EP1516639B1 (fr) | Utilisation de NO pour le traitement de la hypertension pulmonaire persistante du nouveau-né | |
| US5770585A (en) | Homogeneous water-in-perfluorochemical stable liquid dispersion for administration of a drug to the lung of an animal | |
| Hart et al. | Treatment of smoke inhalation by hyperbaric oxygen | |
| JPH03501852A (ja) | エアゾール化したポリエンを用いる肺の真菌感染の予防及び治療方法 | |
| Raskin | Bronchospasm after inhalation of pancreatic dornase | |
| JPH0669957B2 (ja) | グルタチオンのエーロゾル製剤 | |
| CN114533706B (zh) | 一种用于防治呼吸道疾病的雾化吸入制剂及其应用 | |
| Brown et al. | Pathophysiological responses following phosgene exposure in the anaesthetized pig | |
| Cumarasamy et al. | Artificial ventilation in hyaline membrane disease: the use of positive end-expiratory pressure and continuous positive airway pressure | |
| JPWO2021211885A5 (fr) | ||
| US12084695B2 (en) | Treatment for airway cast obstruction | |
| WO1992010207A1 (fr) | Administration orale d'interferon alpha pour traiter les tumeurs malignes des poumons | |
| Fergusson et al. | Nebulized salbutamol in life-threatening asthma: is IPPB necessary? | |
| KR20230009424A (ko) | 호흡 부전 등에 의한 저산소 상태의 대상을 처치하는 것에 이용하는 의약 조성물 | |
| EP1225913B1 (fr) | Utilisation de monoxyde d'azote pour le traitement d'une constriction du conduit aerien | |
| Simpson et al. | Severe ventilatory failure in asthma in children. Experience of 13 episodes over 6 years. | |
| Flenley | New drugs in respiratory disorders: I. | |
| Segal | Advances in inhalation therapy, with particular reference to cardiorespiratory disease | |
| RU220899U1 (ru) | Устройство дыхательного контура для низкопоточной доставки и высокодозной терапии оксидом азота | |
| RU2262343C2 (ru) | Способ лечения гипоксии | |
| WO2000025796A1 (fr) | Traitement de l'asthme a l'aide de fructose-1,6-diphosphate | |
| Katz et al. | Pretreatment with methylprednisolone shortens survival in a canine model of Pseudomonas pneumonia | |
| Georgieff | New Possibilities and Limits with Xenon |